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Introduction: The measurement of cardiospecifi c troponins is pivotal in the diagnostic and prognostic approach of patients with suspected acute 
myocardial infarction (AMI). However, no information is available on the commutability of results between the novel highly-sensitive (HS) troponin 
T (TnT) and I (TnI) immunoassays.
Materials and methods: The study population consisted in 47 consecutive patients presenting at the emergency department (ED) of the Academic 
Hospital of Parma with suspected AMI. TnI was measured with the novel prototype Beckman Coulter HS-AccuTnI immunoassay on Access 2, whereas 
TnT was measured with the Roche HS-TnT immunoassay on Cobas.
Results: Eight out of the 47 patients (17%) were fi nally diagnosed as having an AMI. The overall correlation between TnT and TnI for total patient 
group was acceptable (r = 0.944; P < 0.01). Nevertheless, when the analysis of data was carried out in separate groups according to the fi nal diagno-
sis of AMI, two diff erent equation results were obtained, i.e., HS-TnT = HS-AccuTnI x 0.349 + 20 (r = 0.823; P < 0.01) in non-AMI patients, and HS-TnT 
= HS-AccuTnI x 0.134 + 67 (r = 0.972; P < 0.01) in those with AMI.
Conclusions: This study suggests the existence of two biological relationships between TnI and TnT in plasma, depending on the source of release 
from the myocardium. Moreover, the non-commutability of data between HS-TnT and HS-AccuTnI jeopardizes the clinical decision making, makes it 
impossible to calculate the delta or reference change value using the two biomarkers and to fi nally establish a reliable kinetics of troponin release 
from the injured myocardium.
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hort com nication
Introduction
The measurement of cardiospecifi c troponins is a 
mainstay in the diagnostic and prognostic ap-
proach of patients with suspected acute myocar-
dial infarction (AMI). Reliable evidence has been 
gathered about an excellent correlation between 
the upper measuring range of the new, highly sen-
sitive (HS) Troponin T (TnT) immunoassay and the 
values obtained for the former 4th generation im-
munoassay (1). No information has however been 
provided on the commutability of results between 
TnT and troponin I (TnI) immunoassays, to the best 
of our knowledge. Therefore, the aim of this study 
was to compare the data obtained by the Roche 
highly sensitive Troponin T (HS-TnT) (Roche Diag-
nostics GmbH, Basel, Switzerland) and the novel pro-
totype HS-AccuTnI (Beckman Coulter Inc., Brea CA, 
USA) immunoassays in patients admitted at the 
emergency department (ED) with suspected AMI.
Materials and methods
The study population consisted in 47 consecutive 
patients presenting at the ED of the Academic 
Hospital of Parma with suspected AMI over one 
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week, from the 13th to the 20th of June, 2011. Sam-
ples were immediately collected on patient admis-
sion in vacuum tubes without additive, centrifuged 
at room temperature and 1500 x g, and immedi-
ately tested. TnI was measured with the novel pro-
totype HS-AccuTnI immunoassay, on Access 2 
(Beckman Coulter Inc.). The 99th percentile refer-
ence limit, the optimal imprecision (i.e., total coef-
fi cient of variation ≤ 10%), and limit of detection 
(LOD) are 8.6 ng/L, 8.6 ng/L and 2.1 ng/L (2). TnT 
was measured with the Roche HS-TnT immunoas-
say on Cobas (Roche Diagnostics GmbH). The 99th 
percentile reference limit, the optimal imprecision 
and LOD are 14.0 ng/L, 13.0 ng/L and 2.0 ng/L (3). 
Results were fi nally expressed as median and 95% 
Confi dence Interval (95% CI). The results of HS-TnT 
and HS-AccuTnI immunoassays were analyzed by 
linear regression analysis and Pearson correlation 
coeffi  cient (r).
Results
Eight out of the 47 patients (17%) were fi nally diag-
nosed as having an AMI, according to the estab-
lished criteria (4). The fi nal diagnosis for each pa-
tient was achieved by two independent cardiolo-
gists who reviewed all available medical records 
and results of laboratory tests. The median values 
(95% CI) of HS-TnT and HS-AccuTnI were 31 ng/L 
(3-240 ng/L) and 95 ng/L (5-534 ng/L) in patients 
without AMI, and 651 ng/L (323-1429 ng/L) and 
5568 ng/L (1543-10276 ng/L) in those with AMI. The 
overall correlation of all test results was r = 0.944 (P 
< 0.001), and the relative equation was HS-TnT = 
HS-AccuTnI x 0.138 [95% CI (0.130-0.145)] + 41 [95% 
CI (21-61)]. Nevertheless, when the analysis of data 
was carried out in separate groups according to 
the fi nal diagnosis of AMI (i.e., AMI N = 8; and non-
AMI N = 39), two diff erent results were observed. 
In particular, in the non-AMI group the correlation 
coeffi  cient was 0.823 (P < 0.001) and the equation 
HS-TnT = HS-AccuTnI x 0.349 [95% CI (0.268-0.429)] 
+ 20 [95% CI (6-34)], whereas in the AMI group the 
correlation was higher (r = 0.972; P < 0.001), and 
the equation was also signifi cantly diff erent, i.e., 
HS-TnT = HS-AccuTnI x 0.134 [95% CI (0.102-0.166)] 
+ 67 [95% CI (-142–277)].
Discussion
This is the fi rst investigation assessing the correla-
tion of HS-TnT with the novel HS-AccuTnI in pa-
tients with and without AMI, to the best of our 
knowledge. In the latter category of patients, this 
was especially allowed by the remarkably im-
proved analytical sensitivity of these novel meth-
ods. Although our study is relatively small, the re-
sults attest that two rather diff erent biological re-
lationships exist between TnI and TnT in plasma, 
depending on the source of release of these pro-
teins from the myocardium. In the former instance, 
which is characterized by the physiological renew-
al of the cardiomyocytes or mechanical stretch of 
cardiomyocytes due to pressure or volume over-
load in subjects without AMI (5), the concentration 
of TnT in plasma is nearly one third of that of TnI. 
Conversely, after irreversible ischemic myocardial 
injury and necrosis, the concentration of TnI in 
plasma becomes nearly 10-time higher than that 
of TnT. It is thereby misleading to perform correla-
tion analysis after mixing AMI cases and controls. 
This observation has also important clinical impli-
cations. Due to the increasing diff usion of the “hub 
and spoke” network model in healthcare, which is 
also characterized by centralization of intensive 
FIGURE 1. Linear regression analysis and correlation between 
results of highly sensitive (HS) troponin T (TnT) and I (TnI) in 
47 patients admitted to the emergency department with sus-
pected acute myocardial infarction (AMI). ( non-AMI, N = 39; 
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therapy/intensive treatment cardiology units (6), 
the fi rst sample for troponin testing might be 
drown in a peripheral ED, from where critical pa-
tients might then be transferred to the reference 
hospital of the area. Since in several national set-
tings the peripheral and the core laboratories 
might use diff erent troponin immunoassays (i.e., 
HS-TnI versus HS-TnT), our results clearly attest that 
the non-commutability of data jeopardizes the 
clinical decision making based on results of diff er-
ent immunoassays and, even more importantly, 
makes it impossible to calculate the delta or refer-
ence change value between the fi rst and the fol-
lowing troponin results (7), and fi nally establish a 
reliable kinetics of troponin release from the in-
jured myocardium.
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Jesu li rezultati dobivenih visoko osjetljivim imunokemijskim testovima za 
određivanje koncentracije troponina I i T međusobno zamjenjivi?
Sažetak
Uvod: Određivanje koncentracije srčano-specifi čnog troponina predstavlja osnovni dijagnostički i prognostički pristup bolesnicima sa suspek-
tnim akutnim infarktom miokarda (engl. acute myocardial infarction, AMI). Međutim ne postoje podaci o međusobnoj zamjenjivosti rezultata 
između novih visoko osjetljivih imunokemijskih testova za određivanje koncentracije troponina T (HS-TnT) i troponina I (TnI).
Materijali i metode: Populaciju ispitanika činilo je 47 uzastopnih bolesnika primljenih u hitnu službu (engl. emergency department, ED) Aka-
demske bolnice u Parmi sa sumnjom na akutni infarkt miokarda. Koncentracija TnI određena je novim prototipom imunokemijskog teksta HS-
AccuTnI od tvrtke Beckman Coultera na analizatoru Access2, dok je koncentracija TnT određena imunokemijskim testom HS-TnT tvrtke Roche 
Diagnostics na analizatoru Cobas.
Rezultati: Za osam od 47 (17%) bolesnika naposljetku je postavljena dijagnoza AMI. Ukupna korelacija između TnT i TnI za sve ispitanike bila je 
prihvatljiva (r = 0,944; P < 0,01). Međutim, nakon izvršene analize podataka u odvojenim skupinama prema završnoj dijagnozi AMI, dobivene su 
dvije različite jednadžbe rezultata: HS-TnT = HS-AccuTnI x 0,349 + 20 (r = 0,823; P < 0,01) za ispitanike bez dijagnoze AMI i HS-TnT = HS-AccuTnI 
x 0,134 + 67 (r = 0,972; P > 0,01) za ispitanike s dijagnozom AMI.
Zaključak: Rezultati istraživanja upućuju na postojanje dvije biološke veze između TnI i TnT u plazmi, ovisno iz kojeg djela miokarda dolazi. Štovi-
še, nemogućnost zamjene rezultata dobivenih testovima za HS-TnT i HS-AccuTnI ugrožava kliničko donošenje odluka te onemogućuje izračunava-
nje promijene vrijednosti (delta) ili klinički značajne promjene koncentracije primjenom ova dva biološka biljega te onemogućuje konačnu izradu 
pouzdane kinetike otpuštanja troponina iz ozlijeđenog miokarda.
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